6.83

0.29% 0.00

After Hours: 6.77 -0.06 -0.88%

Profound Medical Corp (PROF)

Overview News Price History Option Chain Discussions Forecast Stock Split

Profound Medical Corp stock is traded at $6.83, with a volume of 134.42K. It is up +0.29% in the last 24 hours and down -2.00% over the past month. Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.

Previous Close:

$6.83

Open:

$6.83

24h Volume:

134.42K

Relative Volume:

0.74

Market Cap:

$244.19M

Revenue:

$16.10M

Net Income/Loss:

$-42.57M

P/E Ratio:

-4.8429

EPS:

-1.4103

Net Cash Flow:

$-38.53M

1W Performance:

+1.78%

1M Performance:

-2.00%

6M Performance:

+6.04%

1Y Performance:

+33.53%

1-Day Range:

$6.71

$6.99

1-Week Range:

$6.735

$7.175

52-Week Range:

$3.76

$8.95

Profound Medical Corp Stock (PROF) Company Profile

Name

Profound Medical Corp

Sector

Healthcare (1113)

Industry

Medical Devices (143)

Phone

647-476-1350

Address

2400 SKYMARK AVENUE, UNIT 6, MISSISSAUGA, ON

Employee

162

Twitter

@profoundmedical

Next Earnings Date

2026-05-07

Latest SEC Filings

PROF's Discussions on Twitter

Compare PROF vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PROF Profound Medical Corp	6.72	248.19M	16.10M	-42.57M	-38.53M	-1.4103
ABT Abbott Laboratories	86.66	152.25B	45.13B	6.28B	7.38B	3.5895
SYK Stryker Corp	312.95	121.33B	25.27B	3.34B	4.57B	8.6334
MDT Medtronic Plc	77.59	100.91B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	57.66	85.88B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	87.56	49.39B	6.30B	1.07B	1.09B	1.8406

Profound Medical Corp Stock (PROF) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-23-24	Initiated	Lake Street	Buy
Jul-16-24	Upgrade	Stifel	Hold → Buy
Nov-28-23	Initiated	Stifel	Hold
Aug-04-23	Downgrade	Raymond James	Strong Buy → Outperform
Mar-21-23	Downgrade	Jefferies	Buy → Hold
Sep-15-20	Initiated	Jefferies	Buy

View All

Profound Medical Corp Stock (PROF) Latest News

May 24, 2026

Profound Medical Q1 2026 Earnings: EPS Beats Estimates, Stock DeclinesEarnings Beat Alert - Newser

May 24, 2026

PROF Q1 2026 Earnings: EPS Surprises to the Upside, Stock Declines 2%Community Pattern Alerts - Newser

May 24, 2026

May 22, 2026

Profound Medical (PROF) Hovers Near Support Amid Modest DeclineFactor Momentum - Newser

May 22, 2026

May 20, 2026

[EFFECT] Profound Medical Corp. SEC Filing - Stock Titan

May 20, 2026

May 18, 2026

Wall Street Analysts See a 59.68% Upside in Profound Medical (PROF): Can the Stock Really Move This High? - Yahoo Finance

May 18, 2026

May 16, 2026

Profound Medical Shareholders Back Board, Question Incentive Plan - The Globe and Mail

May 16, 2026

May 15, 2026

Telix partners with EDAP, Profound on prostate imaging tech - Investing.com UK

May 15, 2026

Profound Medical (NASDAQ: PROF) investors back board, auditor and long‑term incentive units - Stock Titan

May 15, 2026

Telix to Collaborate With EDAP, Profound Medical to Explore PSMA-PET Imaging in Prostate Cancer Therapies - Moomoo

May 15, 2026

Profound Medical Showcases TULSA-PRO Integration with PSMA PET Imaging for Prostate Cancer at AUA2026 - Minichart

May 15, 2026

Profound Medical Q1 earnings call highlights - MSN

May 15, 2026

How Profound Medical Corp. (PROF) Affects Rotational Strategy Timing - Stock Traders Daily

May 15, 2026

May 14, 2026

Profound Medical Highlights TULSA Advances at AUA 2026 - TipRanks

May 14, 2026

Profound Medical (NASDAQ: PROF) to highlight TULSA and PSMA PET integration at AUA2026 - Stock Titan

May 14, 2026

Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026 - The Manila Times

May 14, 2026

Imaging combo to sharpen prostate cancer treatment planning - Stock Titan

May 14, 2026

May 13, 2026

Nearly 70% of Profound Medical shares vote to support full board slate - Stock Titan

May 13, 2026

Profound Medical Annual General and Special Meeting of Shareholders Voting Results - TradingView

May 13, 2026

Profound outlines ~$25M 2026 revenue, anticipates FDA clearance for Siemens Free integration by year-end - MSN

May 10, 2026

May 08, 2026

Profound Medical Q1 Earnings Call Highlights - TradingView

May 08, 2026

Profound Medical revenue up 104% in Q1 2026 - Medical Buyer

May 08, 2026